Martin M. Miner, MDDirector, Men's Health Center
Miriam Hospital
Clinical Associate Professor
of Family Medicine and Urology
Warren Alpert Medical School
of Brown University
Providence, Rhode Island
FACULTY
Adrian S. Dobs, MD, MHSProfessor of Medicine and Oncology
Johns Hopkins University School of Medicine
Division of Endocrinology and Metabolism
Baltimore, Maryland
Robert A. Kloner, MD, PhDProfessor of Medicine
Cardiovascular Division
Keck School of Medicine
University of Southern California
Los Angeles, California
Abraham Morgentaler, MDAssociate Clinical Professor
Urologic Surgery
Harvard Medical School
Boston, Massachusetts
VIDEO TOPICS
Hypogonadism Fundamentals: Diagnosis and Determining Who Is a Candidate for TreatmentIn this clip, we review clinical practice guidelines on the diagnosis and treatment of hypogonadism and who is a candidate for treatment.
Primary Care and Specialist Approaches to Hypogonadism Treatment and Referral
Although the majority of hypogonadism cases can be managed by the primary care clinician, referral to a specialist is appropriate in specific instances. The treatment of hypogonadism and men’s health concerns ideally incorporates a multidisciplinary approach. In this clip, we explore how the urologist, endocrinologist, cardiologist, and primary care clinician are each involved in the management of hypogonadism.
Defining the Associations Between Hypogonadism and Obesity, Type 2 Diabetes, and Cardiometabolic Disease and the Effect of Testosterone Therapy in the Population With These Comorbidities
A well-developed body of evidence suggests that male hypogonadism is associated with type 2 diabetes, obesity, and metabolic syndrome and its components that may increase the risk of cardiovascular morbidity and mortality. In this clip, we discuss the relationships between these conditions and the latest studies exploring the effect of testosterone therapy in the patient populations affected.
Weighing Epidemiologic Evidence and Testosterone Trials With Cardiovascular Endpoints: Evaluating Whether Endogenous and Exogenous Testosterone Are Associated With Increased Mortality or Cardiovascular Risk
Some epidemiologic studies have shown that low endogenous testosterone levels are independently associated with cardiovascular risk factors, and it has been hypothesized that hypogonadism contributes to higher mortality via arterial stiffening, endothelial dysfunction, and increased atherosclerosis. In this clip, we review some of the epidemiologic evidence and discuss what is currently known about the cardiovascular safety of testosterone therapy and what needs further investigation.
Looking at the Proof: Investigating the Inverse Relationship Between Prostate Cancer Risk and Endogenous Testosterone Levels
As screening for prostate cancer increases, some clinicians have expressed concerns about an association between prostate cancer and testosterone therapy. In this clip, we provide the historical context for these concerns, the latest research, and the implications for hypogonadism treatment.
Monitoring Treatment and Reviewing Therapeutic Options
In this clip, we discuss the array of treatment options for hypogonadism as well as suggestions for monitoring prior to and during testosterone therapy.
